The Top 5 Biosimilars Articles for the First Half of 2019

The Center for Biosimilars® recaps the 5 most-read stories of 2019 to date.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

It’s been a busy year for biosimilars, and this week, we’re recapping the 5 most-read stories of 2019 to date.

Number 5: The year opened with price hikes to a number of prescription drugs.

Number 4: The FDA approved another biosimilar trastuzumab product referencing Herceptin.

Number 3: Biosimilar developer Pfizer confirmed that it had cut 5 preclinical biosimilar programs from its portfolio.

Number 2: The FDA released its long-awaited final guidance on demonstrating interchangeability.

Number 1: The FDA approved Samsung Bioepis’ trastuzumab biosimilar.

What will the second half of the year hold for biosimilars? Stay up to date with the key news as it unfolds at

Related Videos
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD
Julie M. Reed
Gillian Woollett, MA, Dphil
Julie M. Reed
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Related Content
© 2023 MJH Life Sciences

All rights reserved.